Zenas BioPharma, Inc.(ZBIO)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,945 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
ZBIO Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Zenas BioPharma, Inc. (ZBIO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ZBIO at 7.4/100 on a 32-signal composite quality model, placing it at rank #2,945 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include profitability (0.2) and free cash flow (0.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Zenas BioPharma, Inc. reports quarterly revenue of $1.0M, net income of $-111.5M, free cash flow of $-57.2M. Top institutional holders of ZBIO by reported 13-F value include FMR, SR ONE CAPITAL MANAGEMENT, NEA Management Company, based on the most recent SEC filings. ZBIO trades on the Nasdaq exchange and files with the SEC under CIK 1953926. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ZBIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Zenas BioPharma, Inc. directly from SEC EDGAR. Zenas BioPharma, Inc.'s 13F Pro composite quality score has ranged between 7 and 28 since 2025, currently 7.4 — a declining long-term trajectory across 52 quarterly and live scoring snapshots.
Revenue
Q2 2026
$1.0M
Net Income
Q2 2026
$-111.5M
Free Cash Flow
Q2 2026
$-57.2M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+100.0% YoYNet Income
-140.6% YoYOperating Income
-133.7% YoYEPS (Diluted)
+29.0% YoYTotal Assets
+3.7% YoYTotal Debt
Op. Cash Flow
-44.0% YoYFree Cash Flow
-43.9% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | $10.0M +100.0% | $5.0M -90.0% | $50.0M | — |
| Net Income | $-377.7M -140.6% | $-157.0M -322.9% | $-37.1M | — |
| Operating Income | $-383.1M -133.7% | $-163.9M -341.2% | $-37.1M | — |
| EPS (Diluted) | $-8.44 +29.0% | $-11.89 +51.0% | $-24.25 | — |
| Total Assets | $383.6M +3.7% | $370.0M +442.6% | $68.2M | — |
| Total Debt | $78.6M | — | — | — |
| Operating Cash Flow | $-172.3M -44.0% | $-119.7M -292.0% | $-30.5M | — |
| Free Cash Flow | $-172.4M -43.9% | $-119.8M -292.2% | $-30.5M | — |
Get alerted when ZBIO's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Zenas BioPharma, Inc. including:
Top Institutional Holders of ZBIO
FMR LLC
$241.3M9,506,701 shSR ONE CAPITAL MANAGEMENT, LP
$127.9M5,037,854 shNEA Management Company, LLC
$102.1M4,023,219 shEnavate Sciences GP, LLC
$99.5M3,919,159 shFEDERATED HERMES, INC.
$79.1M3,116,805 shBlackRock, Inc.
$68.2M2,686,225 shCapital International Investors
$63.5M2,502,912 shPolar Capital Holdings Plc
$61.2M2,412,772 shFairmount Funds Management LLC
$59.9M2,359,025 shSTATE STREET CORP
$52.2M2,055,100 sh
| Fund | Value | Shares |
|---|---|---|
| FMR LLC | $241.3M | 9,506,701 |
| SR ONE CAPITAL MANAGEMENT, LP | $127.9M | 5,037,854 |
| NEA Management Company, LLC | $102.1M | 4,023,219 |
| Enavate Sciences GP, LLC | $99.5M | 3,919,159 |
| FEDERATED HERMES, INC. | $79.1M | 3,116,805 |
| BlackRock, Inc. | $68.2M | 2,686,225 |
| Capital International Investors | $63.5M | 2,502,912 |
| Polar Capital Holdings Plc | $61.2M | 2,412,772 |
| Fairmount Funds Management LLC | $59.9M | 2,359,025 |
| STATE STREET CORP | $52.2M | 2,055,100 |
Companies Similar to ZBIO
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Evommune, Inc.
BioAge Labs, Inc.
CRESCENT BIOPHARMA, INC.
Dianthus Therapeutics, Inc. /DE/
Monte Rosa Therapeutics, Inc.
Upstream Bio, Inc.
uniQure N.V.
Relay Therapeutics, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put ZBIO on your watchlist
Track score changes the day Zenas BioPharma, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ZBIO a good stock to buy?
13F Pro's AI-powered analysis of Zenas BioPharma, Inc. (ZBIO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ZBIO are available on the ZBIO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ZBIO is classified as a mid company.
Which hedge funds own ZBIO?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ZBIO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Zenas BioPharma, Inc.'s investment landscape.